Table 1– Clinical data for the 54 children included in the transcriptome analysis
SACAControlsp-value for difference#
Subjects n171918
Age years14±314±310±50.002
Female/male n7/107/123/15ns+
ACT16±323±2NANA
ICS800 (800–800)360 (200–400)NANA
FEV1 % pred91±2089±11NAns
DRSmethacholine31 (1.6–59)0.8 (0.2–7.7)NA0.01§
Total WBC 109×L−16.4±2.16.0±1.55.6±0.9ns
Eosinophils 109×L−10.3±0.20.3±0.20.2±0.2ns
Neutrophils 109×L−13.3±1.52.5±0.72.7±0.8ns
Lymphocytes 109×L−12.3±0.72.7±0.72.2±0.8ns
FeNO ppb18 (11–38)16 (9–21)NAns
Total IgE kUA·L−1270 (120–740)200 (66–545)NAns§
Atopy %14±8215±79NAns+
  • Data are presented as mean±sd or median (interquartile range), unless otherwise stated. SA: severe asthma; CA: controlled asthma; ACT: asthma control test; ICS: inhaled corticosteroids; FEV1: forced expiratory volume in 1 s; % pred: % predicted; DRSmethacholine: slope of the dose–response curve for provocation with methacholine; WBC: white blood cells; FeNO: exhaled nitric oxide fraction; ns: not significant (p>0.05); NA: not applicable. #: t-test between SA and CA or ANOVA for overall difference between the groups (when possible); : defined as specific IgE >0.35 kU·L−1 to inhalant allergens (Phadiatop®, Phadia AB, Uppsala, Sweden); +: Chi-squared test; §: Wilcoxon rank-sum test was used for difference between SA and CA.